2024-11-0920220258-851X10.21873/invivo.129852-s2.0-85138446312https://hdl.handle.net/20.500.14288/623Background/aim: high-sensitivity C-reactive protein (hs-CRP) is used in the differential diagnosis of maturity-onset diabetes of the young (MODY)-3, but other inflammatory markers have not been investigated in MODY patients. We aimed to compare the serum levels of anti-inflammatory and proinflammatory cytokines between MODY patients and healthy subjects and show the inflammatory features in MODY subtypes. Patients and methods: thirty patients with clinically suspected MODY and 34 healthy controls were included in this study. Next -generation sequencing (NGS) was used for the molecular diagnosis of MODY subtypes. Serum levels of cytokines were measured using a multiplexed cytokine assay and hs-CRP concentration was determined by the immunoturbidimetric assay. Results: the hs-CRP levels were higher in both NGS-confirmed (MODY, n=17) (p=0.009) and NGS-unconfirmed (non-MODY, n=13) patients (p<0.001) than those in controls. However, IL-1 beta (p=0.001), IL-6 (p=0.018), IL-31 (p=0.003), TNF-alpha (p<0.001), and sCD40L (p=0.007) levels of MODY patients and IL-1 beta (p=0.002), IL-31 (p<0.001), IL-22 (p=0.018), and sCD40L (p=0.039) levels of non-MODY patients were lower than those of controls. While hs-CRP levels were lower in MODY3 patients than non-MODY3 patients (p=0.009), IL-17A (p=0.006) and IL-23 (p=0.016) levels for the first time in this study were found to be higher in patients with MODY3 than in patients with other MODY subtypes (p<0.05). Conclusion: MODY patients had lower serum levels of the proinflammatory cytokines IL-1 beta, IL-6, TNF-alpha, IL-31, and sCD40L compared to healthy controls. High IL-17A and IL-23 levels along with low hs-CRP levels may be potential markers to distinguish MODY3 from other MODY subtypes.pdfResearch and experimental medicineJournal Article1791-7549https://doi.org/10.21873/invivo.12985878903300009Q4NOIR03961